Will TherapeuticsMD's Yuvvexy Pass The FDA Muster?
TherapeuticsMD shares were down 44.4 percent in 2016.
By virtue of an advance seen since late February to early April, the stock trimmed some of the losses only to plunge headlong on the news it has received a letter from the FDA related to its pending application of Yuvvexy, or TX-004HR. The stock hasn't recovered since then and has gone only lower.
By virtue of an advance seen since late February to early April, the stock trimmed some of the losses only to plunge headlong on the news it has received a letter from the FDA related to its pending application of Yuvvexy, or TX-004HR. The stock hasn't recovered since then and has gone only lower.